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Abstract: 
Conservative (non-dialytic) kidney care is widely recognized and delivered, 
but until recently has not been clearly defined. This paper provides a clear 
definition of comprehensive conservative care, as holistic patient-centered 
care for patients with end-stage chronic kidney disease. This includes 
interventions to delay progression of kidney disease and minimize 
complications, as well as detailed communication, shared decision making, 
advance care planning, psychological and family support. It does not 
include dialysis.  
Limited epidemiological evidence from Australia and Canada indicates that 
for every new person diagnosed with end-stage kidney disease who 
receives dialysis or transplant, there is one new person that is managed 
conservatively (either actively or not). For older patients (those over 75 or 
80 years) who have higher levels of co-morbidity (such as diabetes, heart 
disease) and poorer functional status, the survival advantage of dialysis 
may be limited, and comprehensive conservative management should be 
considered. Robust comparative evidence remains limited however.  
As well as survival, considerations of symptoms, quality of life, and 
hospital-free days are important for patients and families, and there is 
some evidence that communication about possible conservative 
management options is generally insufficient, even where comprehensive 
conservative care pathways are already established.  
There is almost no evidence about which models of care and which 
interventions might be most beneficial in this population; symptom control 
and the cost-effectiveness of interventions are addressed in the companion 
papers within this series.  
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Abstract 
Conservative (non-dialytic) kidney care is widely recognized and delivered, but until recently 
has not been clearly defined. This paper provides a clear definition of comprehensive 
conservative care, as holistic patient-centered care for patients with end-stage kidney 
disease. This includes interventions to delay progression of kidney disease and minimize 
complications, as well as detailed communication, shared decision making, advance care 
planning, psychological and family support. It does not include dialysis. 
Limited epidemiological evidence from Australia and Canada indicates that for every new 
person diagnosed with end-stage kidney disease who receives dialysis or transplant, there is 
one new person that is managed conservatively (either actively or not). For older patients 
(those over 75 or 80 years) who have higher levels of co-morbidity (such as diabetes, heart 
disease) and poorer functional status, the survival advantage of dialysis may be limited, and 
comprehensive conservative management should be considered. Robust comparative 
evidence remains limited however. 
As well as survival, considerations of symptoms, quality of life, and hospital-free days are 
important for patients and families, and there is some evidence that communication about 
possible conservative management options is generally insufficient, even where 
comprehensive conservative care pathways are already established. 
There is almost no evidence about which models of care and which interventions might be 
most beneficial in this population; symptom control and the cost-effectiveness of 
interventions are addressed in the companion papers within this series. 
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Defining conservative care 
Conservative (non-dialytic) kidney care is widely recognized and delivered, but until recently 
has not been clearly defined. A range of different terms, such as conservative care, maximal 
conservative management, palliative care, and supportive care, have been used in relation 
to non-dialysis care in end-stage kidney disease, but without clear definition. This has 
constrained recognition of the health-care needs of this sector of the end-stage kidney 
disease population, and has prevented systematic study to build evidence on ways to best 
improve care and outcomes.  
 
Box 1: Definition of comprehensive conservative care 
‘Comprehensive conservative care’ is planned holistic patient-centred care for patients with 
Stage 5 (glomerular filtration rate category 5) Chronic Kidney Disease that includes: 
 • Interventions to delay progression of kidney disease and minimize risk of   
       adverse events or complications 
 • Shared decision making 
 • Active symptom management 
 • Detailed communication, including advance care planning 
 • Psychological support 
 • Social and family support 
 • Cultural and spiritual domains of care 
Comprehensive conservative care does not include dialysis. 
From the Kidney Disease | Improving Global Outcomes (KDIGO) Controversies Conference 
on Supportive Care in Chronic Kidney Disease (1)  
 
To counter this, a recent consensus conference (1) proposed a detailed, specific definition 
for conservative care in end-stage kidney disease, suggesting adoption of the term 
‘comprehensive conservative care’ to reflect the full extent of conservative management, 
and providing a full definition (see Box 1) of what comprehensive conservative care should 
include. The conference also proposed three distinct groups within the conservative care 
population (see Box 2), to address concerns about availability of renal replacement therapy 
and options for choice across the spectrum of low-, middle-, and high-income countries. 
 
Box 2: Distinct conservative care populations 
1. Comprehensive conservative care. Conservative care that is chosen or medically advised. 
2. Choice-restricted conservative care. Conservative care for patients in whom resource 
constraints prevent or limit access to renal replacement therapy; therefore, a choice for 
conservative care cannot be recognized. 
3. Unrecognized Stage 5 (glomerular filtration rate category 5) chronic kidney disease. 
Chronic kidney disease is present but has not been recognized or diagnosed; therefore, a 
choice for conservative care cannot be recognized. 
From the Kidney Disease | Improving Global Outcomes (KDIGO) Controversies Conference 
on Supportive Care in Chronic Kidney Disease (1) 
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How common is conservative care? 
 
One of the first considerations is understanding the size of the population of those with 
end-stage kidney disease who are managed conservatively. There is very limited evidence 
on the incidence or prevalence of conservative care of end-stage kidney disease, and 
population-based needs assessments in relation to conservative care are rare. In 2011, a 
detailed whole population-based study was published in Australia to estimate the total 
incidence of end-stage kidney disease (2), including (for the first time) both those treated 
with renal replacement therapy and those receiving conservative care. Previous evidence on 
end-stage kidney disease from the national and international Renal Registries has been 
limited to those with dialysis or transplant. The authors identified 21,500 new cases of end-
stage kidney disease in Australia during the period 2003 – 2007  (2); this amounted to 21 
cases per 100,000 people (20.9 per 100,000 population, with 95% confidence intervals of 
18.3 – 24.0 per 100,000 population). For every new case who received dialysis or transplant, 
there was about one new case that did not.   
 
A recent community-based cohort study in Canada demonstrated that, during median 
follow-up of 4.4 years of 1,816,824 adults with measured eGFR in Alberta, Canada, 5.36% 
died, with 0.18% who developed kidney failure that was treated and 0.17% who developed 
kidney failure that was managed conservatively (3).
 
As in the Australian population based 
study (1), for every new case who received dialysis or transplant, there was about one new 
case that did not, and rates of untreated kidney failure were consistently higher at older 
ages. Both studies indicate that the incidence of advanced kidney disease in older people 
may be higher than previously thought, and certainly there are greater than expected rates 
of untreated kidney failure among the oldest patients. It may be that further population-
based studies in other countries would show similarly higher than expected levels of 
conservative management of end-stage kidney disease.  
 
In interpreting these findings, there are some major limitations. First, national data is only as 
yet available from Australia and Canada, and may not apply to other countries and contexts. 
Secondly, just as dialysis patterns have changed over time, so it is probable that patterns of 
conservative care have changed over time. It is worth noting that in the Australian whole 
population-based study, neither the overall proportion of new cases managed with 
conservative care nor the age standardized rate of conservative care consistently changed 
over time period 2003 – 2007, but this is a relatively short timeframe, and further study 
across more extended time periods is needed. Thirdly, and perhaps most important of all, 
this data relates only to high income countries; the limited availability of dialysis in some 
low- and middle-income countries may have a profound impact on the apparent prevalence 
of ‘conservative management’, and underlines the importance of defining and 
understanding the different sectors of the population who are managed without dialysis (as 
defined in Box 2). 
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What is the evidence on survival in conservative care? 
 
A further consideration is survival of those managed without dialysis. One of the main 
challenges in studying and comparing survival between dialysis and conservative 
populations is the bias inherent in the pathway decision. Those who are more fit usually opt 
for dialysis, and many choose or are advised to have conservative management because of 
co-morbidity or other factors which in themselves adversely influence survival. Without 
randomization into either group, it is difficult to attribute survival differences to either 
dialysis or conservative management. In addition, many studies do not compare survival, 
hospital days and symptoms, or quality of life between the two populations; any meaningful 
comparison needs to consider not only survival, but also the nature of any additional days of 
survival. Days spent attending or in hospital, or with poor quality of life are not rated as 
highly by patients as hospital-free days, and days with good quality of life (4). 
 
The key evidence on survival of patients managed conservatively can be distilled from 
fourteen studies (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18). These are 
excellently summarized in the systematic review by O’Connor (19), with later studies by 
Silva Gane et al (15) and Hussain (18). In the absence of randomized controlled trials 
(ethically and practically difficult, if not impossible), each of these studies is flawed in one 
way or another.  Only about half (6) (7) (10) (11) (13) (14) (15) (18) compare survival 
between conservative patients and those on dialysis. The main flaws relate to significant 
differences in the comparison groups with regard to age profiles, how conservative/dialysis 
decisions were made, varying time from which survival is measured(including computing or 
assuming actual or putative ‘dialysis start’ dates), likely changes in referral and dialysis 
practices over recent decades, and the reality that it is only truly legitimate to compare 
survival outcomes when each group is eligible for both treatment options (20). Some studies 
provide further context for the end-stage kidney disease and report co-morbidity or level of 
dependence/performance but scoring systems vary and the Charlson score in particular may 
"double count” or over-score age. In contrast, frailty - which is very common in this 
population and independently associated with increased mortality - is rarely measured or 
reported.  
 
An additional challenge is that the conservative care population is heterogeneous. It 
includes at least three groups of patients whose survival is likely to be very different; first, 
those suitable for dialysis who choose not to receive it, second, older people with high co-
morbidity where dialysis is not offered, and third, patients who lack capacity and may not 
always be offered dialysis. Although some of the studies try to make these distinctions, the 
numbers in the conservative management arms are often small and difficult to analyze with 
precision.  In France, a multicenter prospective cohort study of 581 older patients (mean 
age 82 years) with end-stage kidney disease has shown that, despite a high prevalence of 
comorbidities, most patients are autonomous and living at home. At inclusion, 43% 
postponed the dialysis decision due to stable estimated glomerular filtration rate, 17% were 
under evaluation, 24% chose dialysis, and 16% decided not to have dialysis (21). Szeto et al 
present data on 25 patients who were considered suitable for but declined dialysis; and 
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contrasted this group with 38 patients who were not considered suitable for dialysis, mainly 
because of multiple co-existing medical illnesses. The former ‘declining group’ were younger 
and less co-morbid than the latter group, and yet had no difference in survival (17). Another 
confounder is that most studies do not address survival advantage/excess mortality of 
patients, in relation to life expectancy of age-matched period-specific individuals in the 
general population.  
 
Among the key survival studies, the work by Joly studying those 80 years and over (6) is 
notable for long follow up (up to 12 years) so that differences in referral patterns could be 
sought over different time periods. Those not put forward for dialysis were of similar age 
but were more likely to be socially isolated, referred later, diabetic, and have poorer 
performance.  Survival was significantly longer in the dialyzed group (28.9 versus 8.9 
months). Usefully, the 2.4 year life expectancy of the dialyzed octogenarians was related to 
population norms, and represented about one quarter to one third of the life expectancy of 
the general population over 80 years as reported in national life expectancy statistics in 
France at the time.  In contrast, the most widely cited paper of Smith et al (7) is based on 
very small numbers (10 and 26 respectively), comparing those recommended not to dialyze 
who nevertheless decided to dialyze, and those who followed the recommended 
conservative pathway. Their finding of no significant survival advantage (8.3 months versus 
6.3 months) between these frail elderly patients was important despite the small numbers, 
and despite the fact that a putative dialysis initiation date was based on eGFR of <10 ml/min 
estimated using the Cockroft-Gault formula.  In this study, 65% of the deaths occurring in 
the dialyzed patients took place in hospital compared with 27% in the conservative group 
(used as a surrogate quality indicator). 
 
Carson (13) attempted to “start the clock” at an equivalent time in the comparative groups 
(all incident patients 70 years and older) by computing ‘putative’ dialysis start times (e-GFR 
10.8ml/min/m2) which mirrored practice in the dialysis group (13).  They showed significant 
survival advantage in the dialyzed group (37.8 versus 13.9 months), but the conservative 
group were approximately 10 years older; statistical corrections could not be made to 
correct for this age difference because of the small numbers.  The conservative patients 
were more likely to die at home or in a hospice (again, used as an indirect quality marker) 
and the authors computed that every day of additional survival was almost at the expense 
of a day spent either as an inpatient or attending hospital for dialysis (hospitalization 0.069 
versus 0.043 hospital days per patient days survived) (13).  A different approach was 
adopted by Murtagh et al, who measured survival from estimated GFR < 15 mL/min (10). 
They confined their analysis to all those with Stage 5 chronic kidney disease over 75 years 
known to nephrology clinic. Once again, the overall survival was better in the dialysis group 
but this advantage was lost in patients with high comorbidity.  There are a number of 
caveats to this study. No ‘late presenters’ were included (so this may not reflect real life 
practice and cannot be compared with studies where all incident patients are included).  
The age of the conservative group was 4 years older than the dialysis group, and perhaps 
most importantly, the analysis was on an ‘intention to treat’ basis. 24 patients (24/52) who 
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chose the dialysis pathway did not actually receive dialysis by the study end either because 
they died (n= 8) or because dialysis had not yet started (n= 16).  
 
Szeto reported on survival of 63 conservative patients, and while these authors did not 
attempt to compare conservative and dialysis groups, they do (like Carson et al) provide 
useful data on the sub-group who declined dialysis (n= 25) (17). These were on average a 
decade younger and had much lower co-morbidity scores but – importantly - their survival 
was not significantly different from the conservative group. The median survival from the 
date of needing dialysis (7mls/min) was 6.58 months. Of note also only 36/63 were deemed 
to have died from uraemia, with other unrelated deaths occurring both before (n= 12) and 
after the theoretical date of needing dialysis (n=7).  Taking this study and inferring from 
other studies (6) (7) (13), there is fair evidence that the median survival from e-GFR 6-7 
ml/min is around 6 months.  
 
The more recent papers (14) (18) offer the best available evidence on survival.  Work by 
Chandna and colleagues spans an 18 year period and involving 844 patients, 155 (18%) of 
whom received conservative care (14).  Conservative patients were older and had higher co-
morbidity.  Again there was an overall survival advantage to dialysis (mean survival 21.2 
versus 67.1 months p<0.001).  However (as earlier studies had indicated, but less robustly), 
for patients over 75 years the survival advantage of dialysis reduced to only 4 months (non-
significant) when corrected for age, high co-morbidity and diabetes. Similarly, in a 
retrospective observational study of patients over the age of 70 years attending pre-dialysis 
clinic comparative survival, Hussain reported hospital admission and palliative care access 
outcomes between patients managed conservatively or choosing renal replacement therapy 
(18).  Survival, measured from three time points for both groups (e-GFR was <20mL/min, 
<15 mL/min and <12 mL/min), showed that dialysis conferred a significant survival 
advantage.  However, there was a significant reduction in the effect of dialysis pathway on 
survival for those with high Charlson comorbidity index.  Hospital admissions were greater 
and chances of dying at home were less in the dialysis patients. There was no survival 
advantage from dialysis in the >80 year olds with high co-morbidity or poor functional status 
at all levels of disease severity.  
 
 
What about symptoms, quality of life and illness experience in conservative care? 
 
It is not only survival that is important, but crucially the symptoms, quality of life and 
experience of illness on the conservative management pathway. Once again there is limited 
evidence. O’Connor’s systematic review provides the best summary of evidence about 
symptoms and quality of life (19).  Six studies describe symptom burden and/or quality of 
life.  Most are cross sectional in design and all received a level 2 - or intermediate - strength 
of recommendation taxonomy rating in the review (19) (22).  Three studies used the 
Memorial Symptom Assessment Schedule to collect data (23) (24) (25), while one study 
used a modified POSs (26). Three articles directly measured quality of life (11) (25) (27), 
using standardized tools. One study also used interviews (11) .  
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All report significant symptom burden in those undergoing conservative care, with numbers 
of symptoms varying from 6.8 to 17 per individual patient.  These studies were remarkably 
consistent in terms of reporting similar symptoms and similar patterns of prevalence.  
Where reported, there was a considerable increase in symptoms in the month prior to 
death (24). Evidence on management of symptoms is included in (cross reference to this 
paper in series). Three of the studies (11) (25) (27) included a comparison group. Since the 
systematic review of this evidence, Da Silva Gane and colleagues have published further 
evidence reporting quality of life assessments every three months for up to three years in 
patients with advanced, progressive chronic kidney disease (late stage 4, early stage 5) 
managed conservatively or by dialysis (15).  This is the only longitudinal study which 
contrasts conservative and dialysis management; conservative patients were older, more 
dependent and more highly comorbid with poorer physical health and higher anxiety levels 
than dialysis patients.  Their most important finding however was that the conservative 
patients maintained quality of life, while life satisfaction decreased significantly after dialysis 
initiation in the dialysis group. Mental health, depression, and life satisfaction scores were 
overall similar in the two groups at the start of the study. Brown and colleagues have also 
reported survival, symptom burden, and quality of life in conservatively-managed patients 
(4), including 273 pre-dialysis patients who had usual nephrology care and 122 non-dialysis 
pathway patients who also attended a renal supportive care clinic. Median survival in the 
latter group was 16 (interquartile range, 9, 37) months. With the renal supportive care clinic 
input, 57% of the non-dialysis patients had stable or improved symptoms over 12 months 
and 58% had stable or improved QOL.  
 
Although O’Connor and colleagues have proposed that additional head to head studies are 
needed to compare the symptoms of age-matched dialysis patients, they also felt that the 
current available studies suggested that quality of life was not significantly different in 
conservative patients as in dialysis patients (19). The more recent work by Da Silva Gane and 
colleagues confirms this, and the work by Brown et al suggests that renal supportive care 
clinics can be effective in controlling symptoms and maintaining quality of life, although the 
specific interventions need further study.   
 
Beyond physical and psychological symptoms and quality of life, spiritual care needs have 
also been considered, although critically, in all advanced kidney disease patients rather than 
specifically in the conservative population. In a prospective cohort study of 253 stage 4 and 
5 chronic kidney disease and dialysis patients in Canada, patients reported a mean of 2.9 ± 
2.6 spiritual needs, with 69% of patients reporting at least one spiritual need. 32% of 
patients had high spiritual needs (defined as reporting ≥ 5 of the seven needs). Spiritual 
needs were associated with age, gender, race, marital status, dialysis modality, time on 
dialysis, or comorbidity (28). A further study using the same cohort found that adjustment in 
the domains of psychological distress and extended family relationships appears to mediate 
some of the beneficial effect of existential well-being on health-related quality of life. 
Spirituality, however, provides unique variance in patients' quality of life, independent of 
their psychosocial adjustment (29).  
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A final piece of important evidence relates to the impact on family of caring for someone 
with chronic kidney disease stage 5. Work undertaken in the United Kingdom (30) 
investigated this, and identified confusion about the nature of conservative kidney 
management. Carers were not aware of the palliative nature of conservative care or the 
approaching end-of-life issues, and this highlighted some of their unmet support needs. This 
resonates with evidence directly from patients themselves; that patients' expectations of 
conservative care are strongly influenced by what is communicated to them by renal staff 
(31). Even in renal units with established conservative care pathways, there is often only 
limited information available to patients and families about illness progression and what to 
expect as the illness progresses. 
  
Conclusion 
 
Evidence on conservative care remains limited. The best evidence is on survival; this does 
not necessarily reflect what matters most to patients with end-stage kidney disease and 
their families; instead it reflects what has been studied to date.  The published comparative 
survival outcomes between dialysis and conservative management suffer from inherent 
methodological flaws which limit any conclusions.  
 
There is no doubt that – in general - dialysis is associated with a significant survival 
advantage, but this advantage reduces notably for older people with major co-morbidity 
and poorer functional status. Quality of life, symptoms, and hospital-free survival may be at 
least as important to consider and actively manage. Before starting kidney replacement 
therapy, there should be a shared decision-making process based on understanding of 
prognosis, the potential benefits and harms of therapy, and patient values, goals, and 
preferences (32). It is not yet known which the best models of care or interventions are for 
those managed conservatively without dialysis. The limited evidence on cost-effectiveness is 
summarized in (cross reference to this paper in series), but further study of best ways to 
improve and maintain quality of life, as well as survival, are needed. 
 
The perspectives on comprehensive conservative care may vary between countries, 
according to the availability of renal replacement therapy – this is important, and 
characterizing the different conservative care populations can help. However, there is 
consensus on how comprehensive conservative care can be defined, and what it includes, 
and adopting this definition and consistency in what is delivered will help to support service 
development and future research.  
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